Cost-effectiveness of strict "get to goal" treatment directives in the treatment of younger patients with newly diagnosed type 2 diabetes mellitus (T2DM)

被引：0
|
作者：
Willis, M. [1 ]
Borg, S. [1 ]
Persson, U. [1 ]
Neslusan, C. [2 ]
机构：
[1] Swedish Inst Hlth Econ, IHE, Lund, Sweden
[2] Johnson & Johnson, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2007年 / 10卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)64969-8
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A260 / A260
页数：1
相关论文
共 50 条
  • [21] DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
    Elgart, J. F.
    Prestes, M.
    Gonzalez, L.
    Asteazaran, S.
    Aiello, E.
    Garrido Lecca, S.
    Alvarez, A.
    Roberts, M.
    Cortes Cuadra, P.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2014, 17 (03) : A248 - A248
  • [22] Mechanism of metabolic surgery for the treatment of Type 2 Diabetes Mellitus (T2DM)
    Leishman, David J.
    Ikramuddin, Sayeed
    Naitoh, Takeshi
    MINI-INVASIVE SURGERY, 2023, 7
  • [23] The cost-effectiveness of canagliflozin (CANA) versus sitagliptin (SITA) as third-line therapy in the treatment of type 2 diabetes mellitus (T2DM) in the UK
    Thompson, G.
    Schroeder, M.
    Neslusan, C.
    Willis, M.
    Johansen, P.
    Teschemaker, A.
    DIABETOLOGIA, 2014, 57 : S330 - S330
  • [24] The Cost-Effectiveness of Canagliflozin (CANA) vs. Sitagliptin as an Add-on to Metformin (MET) in the Treatment of Type 2 Diabetes Mellitus (T2DM) in the US
    Martin, Silas
    Neslusan, Cheryl
    Vo, Lien
    Teschemaker, Anna
    Johansen, Pierre
    Willis, Michael
    DIABETES, 2014, 63 : A310 - A310
  • [25] COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA
    Minshall, M. E.
    Swan, T.
    Slusarek, B.
    Ikramuddin, S.
    VALUE IN HEALTH, 2008, 11 (06) : A507 - A507
  • [26] THE IMPORTANCE OF HBA1C EVOLUTION IN COST-EFFECTIVENESS MODELING OF TYPE 2 DIABETES MELLITUS (T2DM)
    Willis, M.
    He, J.
    Neslusan, C.
    Johansen, P.
    Worbes-cerezo, M.
    VALUE IN HEALTH, 2012, 15 (07) : A500 - A500
  • [27] ASSESSING THE INFLUENCE OF INCORPORATING SECONDARY CARDIOVASCULAR EVENTS INTO A TYPE 2 DIABETES MELLITUS (T2DM) COST-EFFECTIVENESS MODEL
    McEwan, P.
    Evans, L. M.
    Bergenheim, K.
    VALUE IN HEALTH, 2010, 13 (07) : A293 - A293
  • [28] DEVELOPMENT OF A MODEL TO ASSESS THE COST-EFFECTIVENESS OF THERAPIES FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) FOLLOWING A REFERENCE MODEL FRAMEWORK
    Aguiar-Ibanez, R.
    Palencia, R.
    Kandaswamy, P.
    Flavin, J.
    Gauthier, A.
    Davies, M. J.
    VALUE IN HEALTH, 2014, 17 (07) : A562 - A562
  • [29] Effectiveness of Intragastric Balloon Associated with Diet on Treatment of Patients with Type 2 Diabetes (T2DM)
    Reimao, Silvia M.
    Silva, Maria Elizabeth R.
    Mestieri, Luiz Henrique M.
    Nunes, Gabriel C.
    Souza, Thiago F.
    Santo, Marco Aurelio
    Santos, Rosa F.
    Moura, Eduardo G. H.
    DIABETES, 2017, 66 : A687 - A688
  • [30] COST-EFFECTIVENESS OF DAPAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN PERU
    Elgart, J. F.
    Gonzalez, L.
    Prestes, M.
    Manrique, H.
    Solorzano, J.
    Gagliardino, J. J.
    VALUE IN HEALTH, 2016, 19 (03) : A203 - A203
12345